Clinical Trial Update: Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab [Phase 2]

View source ↗

Summary

Phase 2 trial of trastuzumab deruxtecan in first-line HER2-positive locally advanced or metastatic breast cancer patients resistant to trastuzumab and pertuzuma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2026-03-12